Literature DB >> 8003126

Serum level of carbohydrate-deficient transferrin as a marker of alcoholic liver disease.

M Yamauchi1, J Hirakawa, Y Maezawa, F Nishikawa, Y Mizuhara, M Ohata, H Nakajima, G Toda.   

Abstract

Serum levels of carbohydrate-deficient transferrin (CDT) were assayed in 87 patients with alcoholic liver disease, 25 alcoholics without liver disease, 25 cases with viral liver disease and 37 healthy subjects, by two different methods (Pharmacia CDT RIA kit and Axis % CDT kit). The serum level of Pharmacia-CDT was significantly higher in the patients with alcoholic liver disease (38.9 +/- 2.8 U/l) compared to the normal subjects (18.9 +/- 0.2 U/l), alcoholics without liver disease (21.7 +/- 1.5 U/l) and non-alcoholic liver disease (viral liver disease) (23.4 +/- 1.6 U/l) (P < 0.001). The serum level of Axis-CDT was also significantly higher in the patients with alcoholic liver disease (4.22 +/- 0.48%) compared to the normal subjects (0.84 +/- 0.14%), alcoholics without liver disease (1.14 +/- 0.23%) and non-alcoholic liver disease (1.84 +/- 0.29%) (P < 0.001). A significant correlation was found between serum levels of CDT determined by the two kits (r = 0.718, P < 0.001). The serum level of Axis-CDT was significantly higher in patients with alcoholic hepatitis compared to the normal subjects (P < 0.005), while the serum level of Pharmacia-CDT was not increased in the patients with alcoholic hepatitis. These results indicate that determination of serum CDT levels is a useful marker of alcoholic liver disease, not a marker for alcohol consumption. Axis-CDT is more useful than Pharmacia-CDT for assaying the serum level of CDT in patients with alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8003126     DOI: 10.1093/alcalc/28.supplement_1b.3

Source DB:  PubMed          Journal:  Alcohol Alcohol Suppl        ISSN: 1358-6173


  3 in total

Review 1.  Detection of alcoholic liver disease.

Authors:  H Gordon
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease.

Authors:  A DiMartini; N Day; T Lane; A T Beisler; M A Dew; R Anton
Journal:  Alcohol Clin Exp Res       Date:  2001-12       Impact factor: 3.455

3.  Identification of serum insulin-like growth factor binding protein 1 as diagnostic biomarker for early-stage alcohol-induced liver disease.

Authors:  Heng-Hong Li; Kathryn Doiron; Andrew D Patterson; Frank J Gonzalez; Albert J Fornace
Journal:  J Transl Med       Date:  2013-10-23       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.